KAE609 (Cipargamin)

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

NVSPhase 2$274.7B

KAE609 (Cipargamin) Phase 2 Results Expected

KAE609 (Cipargamin)• Uncomplicated Plasmodium Falciparum Malaria327

Jun 9Estimated

00%

Competitive Landscape

0 competitors in Uncomplicated Plasmodium Falciparum Malaria

Drug Information

Target Indication

Uncomplicated Plasmodium Falciparum Malaria

Clinical Trial

Last updated: 4/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Non-alcoholic Fatty Liver Disease (NAFLD)

Heart Transplantation

Influenza

Diabetic Retinopathy

Meningococcal Meningitis